<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04973774</url>
  </required_header>
  <id_info>
    <org_study_id>BADstudy</org_study_id>
    <nct_id>NCT04973774</nct_id>
  </id_info>
  <brief_title>A Multi-center Prospective Study of Branch Atheromatous Disease in China</brief_title>
  <official_title>A Multi-center Prospective Study of Branch Atheromatous Disease in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Branch atheromatous disease (BAD), is regarded as one of the important etiologies for acute&#xD;
      isolated subcortical infarction, especially in Asian population. However, due to the fact&#xD;
      that the existing imaging techniques cannot depict small vessel changes, the clinical&#xD;
      diagnosis, therapy and research of BAD are facing challenges. We have started a multi-center&#xD;
      prospective observational study of BAD in China, aiming at establishing a large-sample&#xD;
      clinical-radiological cohort of BAD, analyzing predictors for functional outcome, and&#xD;
      exploring the efficacy of tirofiban on BAD. A standardized Case Report Form (and eCRF on&#xD;
      website) is used to collect baseline and follow-up information on epidemiological, clinical,&#xD;
      radiological（MRI, SWI, MRA, HRMRI,3TVWI）and blood test. The primary outcome was mRS on 90&#xD;
      days with blind evaluation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>modified ranking score</measure>
    <time_frame>90 days</time_frame>
    <description>modified ranking score on 90 days, range:0-6scores; higher score means worse outcome</description>
  </primary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Cerebral Infarction</condition>
  <condition>Disease</condition>
  <condition>Magnetic Resonance Imaging</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Study population will include all acute ischemic stroke patients meeting the inclusion and&#xD;
        exclusion criteria in all centers of our study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age:18-80years&#xD;
&#xD;
          2. Acute cerebral infarction:if the clinical manifestations are TIA, new infarct lesions&#xD;
             should be found on DWI at the same time.&#xD;
&#xD;
          3. The time from onset to enrollment is less than 72 hours. If the onset time was&#xD;
             unknown, the time of last known free of new ischemic symptoms to enrollment is less&#xD;
             than 72h.&#xD;
&#xD;
          4. Meet the following radiological criterial： 1) DWI infarct: single (isolated) deep&#xD;
             (subcortical) infarct. 2) The culprit vessels are the lenticulostriate artery or the&#xD;
             para-pontine median artery, and the infarct lesion on DWI conforms to one of the&#xD;
             following characteri stics(A/B): A. Lenticulostriate artery: ① &quot;comma-like&quot; infarct&#xD;
             lesions with &quot;fan-shaped&quot; extension from bottom to top in the coronary position; OR ②&#xD;
             ≥3 layers (layer thickness 5-7 mm) on axial DWI images of the head; B. Para-pontine&#xD;
             median artery: the infarct lesion extends from the deep pons to the ventral pons on&#xD;
             the axial DWI of the head.&#xD;
&#xD;
        3) No ≥50% stenosis on the parent artery of the criminal vessel (i.e. corresponding basilar&#xD;
        or middle cerebral artery) (confirmed by MRA or CTA or DSA).&#xD;
&#xD;
        5.Signed informed consent by the patient or legally authorised representatives&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Intracranial hemorrhagic diseases, vascular malformations, aneurysms, brain abscesses,&#xD;
             malignant space occupying lesions or other non-ischemic intracranial lesions observed&#xD;
             by baseline head CT and MRI, MRA/CTA/DSA;&#xD;
&#xD;
          2. There was ≥50% stenosis of extracranial vessels with ipsally serial relationship&#xD;
&#xD;
          3. Cardiogenic embolism: atrial fibrillation, myocardial infarction, valvular heart&#xD;
             disease, dilated cardiomyopathy, infective endocarditis, atrioventricular block&#xD;
             disease, heart rate less than 50 beats /min&#xD;
&#xD;
          4. Have received or plan to receive acute endovascular treatment after onset of the&#xD;
             disease&#xD;
&#xD;
          5. stroke caused by other clear causes, such as moyamoya disease, arterial dissection,&#xD;
             vasculitis, etc&#xD;
&#xD;
          6. mRS score prior to the onset of the disease was ≥2 points&#xD;
&#xD;
          7. Known malignant tumor&#xD;
&#xD;
          8. Life expectancy ≤6 months&#xD;
&#xD;
          9. Can not tolerate 3T MRI examination&#xD;
&#xD;
         10. Pregnant or lactating women&#xD;
&#xD;
         11. Participation in another clinical within 3 months before enrollment, or taking part in&#xD;
             another ongoing study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bin Peng, Phd,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shengde Li, PhD,MD</last_name>
    <phone>17896002828</phone>
    <email>lishengde.medicine@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jun Ni, Phd,MD</last_name>
    <phone>8601069154059</phone>
    <email>pumchnijun@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shengde li</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shengde Li, MD,PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 17, 2021</study_first_submitted>
  <study_first_submitted_qc>July 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Bin Peng</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>branch atheromatous disease</keyword>
  <keyword>prospective</keyword>
  <keyword>tirofiban</keyword>
  <keyword>antiplatelet</keyword>
  <keyword>prognosis</keyword>
  <keyword>Lenticulostriate artery</keyword>
  <keyword>HRMRI</keyword>
  <keyword>3TVWI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

